Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Chronic Spontaneous Urticaria (ARROYO)
NCT04612725Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of benralizumab in chronic spontaneous urticaria (CSU) (5 arms), sponsored by AstraZeneca. Primary endpoint: Itch Severity Score Over 7 Days at Week 12. Started Oct 2020; status: terminated.
02
Drugs
benralizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04612725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612725.